All Oncology News

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes.

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

Carma L. Bylund, PhD, discussed the findings from a pilot study of a fellowship-level program for clinical trial communication skills.

Yale Cancer Center researchers publish promising study of dual inhibition of PD1 and macrophage migration inhibitory factor.

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

FDA grants fast track status to MT-125, a first-in-class NMII inhibitor, aiming to bring a novel treatment option to patients with aggressive glioblastoma.

Specific HLA types were not found to be associated with robust mKRAS-specific T-cell responses after treatment with ELI-002 7P in patients with PDAC.

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

Roswell Park-led study reveals benefits of combining adoptive cell therapy with immune checkpoint inhibitors in ovarian cancer.

Neladalkib showed durable responses and good tolerability in ALK-positive solid tumors, including TKI-pretreated patients, in early ALKOVE-1 results.

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Sara A. Hurvitz, MD, FACP, discusses the design of VIKTORIA-1, key efficacy and safety findings, and how these data may influence breast cancer management.

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.